The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
Colorectal cancer is next for VEGF bispecifics
Pumitamig is the latest to be tested in first-line disease.
A new multiple myeloma race heats up
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
A new myeloid cell engager enters the clinic
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
A mystery Moderna asset hits the clinic
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
